Publications by authors named "Jeffrey Weitz"

Claim this Profile
R
Relationship between Surgery and Trauma and Risk of Recurrence in Patients with an Associated First Venous Thrombotic Event: A Nested Case-Control Study.
Tiago Gregorio, Katherine J Creeper, Leopoldo Pagliani, Rui Providencia, Adrian Buzea, Jeffrey I Weitz

Thromb Haemost· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologically Active Implants Prevent Mortality in a Mouse Sepsis Model.
Martin Stark, Fereshteh Bayat, Sara Rahmani, Mathura Thirugnanasampanthar, Taylor Kramer, Jeffrey I Weitz

Adv Healthc Mater· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superficial Vein Thrombosis: A Review.
Gregory Piazza, Darsiya Krishnathasan, Nada Hamade, Francisco Ujueta, Giovanni Scimeca, Jeffrey I Weitz

JAMA· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The win ratio for evaluating edoxaban versus dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE cancer trial.
Nick van Es, Luuk J J Scheres, Kristen M Sanfilippo, Harry Büller, Marc Carrier, Jeffrey I Weitz

J Thromb Haemost· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis.
Jackie Trink, Ifeanyi Kennedy Nmecha, Katrine Pilely, Renzhong Li, Zi Yang, Jeffrey I Weitz

JCI Insight· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism.
Davide Capodanno, John H Alexander, M Cecilia Bahit, John W Eikelboom, C Michael Gibson, Jeffrey I Weitz

Nat Rev Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.
Siddharth M Patel, Robert P Giugliano, David A Morrow, Erica L Goodrich, Sabina A Murphy, Jeffrey I Weitz

JAMA Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-Cleaning Menstrual Cups with Plant-Based Biodegradable Superabsorbent Fibrous Tablets for Hygienic and Sustainable Period Care.
Shaghayegh Moghimikandelousi, Fereshteh Bayat, Lubna Najm, Rida A Malik, Aishwarya Bhavan, Jeffrey I Weitz

ACS Appl Mater Interfaces· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of REGN9933 and REGN7508 for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.
Jeffrey I Weitz, Aaron P Kithcart, Meagan P O'Brien, Oren Levy, Ethan Marin

Lancet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of milvexian alone or with heparin on catheter-induced clotting and thrombin generation.
Ruiqi Yin, James C Fredenburgh, Jeffrey I Weitz

J Thromb Haemost· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOAC-Stop reverses the anticoagulant effect of asundexian and milvexian.
Ella K Fitzpatrick, James C Fredenburgh, Jeffrey I Weitz

J Thromb Haemost· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
Samer Al Said, Siddharth M Patel, Robert P Giugliano, David A Morrow, Erica L Goodrich, Jeffrey I Weitz

Circulation· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex differences in venous thromboembolism outcomes: findings from the GARFIELD-VTE registry.
Paolo Prandoni, Meg Fluharty, Sebastian Schellong, Henri Bounameaux, Sylvia Haas, Jeffrey I Weitz

Eur J Intern Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).
C Michael Gibson, M Cecilia Bahit, Roxana Mehran, Shamir R Mehta, Rasha Al Lamee, Jeffrey I Weitz

Am Heart J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study.
Vincent R Lanting, Kika van Bergen En Henegouwen, Floris T M Bosch, Michael A Grosso, Annelise Segers, Jeffrey I Weitz

J Thromb Haemost· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71.
Siddharth M Patel, Robert P Giugliano, David A Morrow, Sanobar Parkar, Hannah Shapiro, Jeffrey I Weitz

J Am Coll Cardiol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH: reply.
Jerrold H Levy, Joseph R Shaw, Jean M Connors, James Douketis, Jeffrey I Weitz

J Thromb Haemost· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosite crosstalk in thrombin.
James C Fredenburgh, Jeffrey I Weitz

J Thromb Haemost· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XI before X: The Promise of Factor XI Inhibitors.
Jeffrey I Weitz, Husam Alzayer

Kidney Int Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
Christian T Ruff, Siddharth M Patel, Robert P Giugliano, David A Morrow, Bruce Hug, Jeffrey I Weitz

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.
Sneha S Jain, Kenneth W Mahaffey, Karen S Pieper, Wataru Shimizu, Tatjana Potpara, Jeffrey I Weitz

Am Heart J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence.
Marco Zuin, Behnood Bikdeli, Jennifer Ballard-Hernandez, Stefano Barco, Elisabeth M Battinelli, Jeffrey I Weitz

J Am Coll Cardiol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement.
Marc P Bonaca, Geoffrey D Barnes, Rupert Bauersachs, Youssef Bessada, Michael S Conte, Jeffrey I Weitz

J Am Coll Cardiol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arterial Thrombosis: Present and Future.
Jeffrey I Weitz

Circulation· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.
Job Harenberg, Robert C Gosselin, Adam Cuker, Cecilia Becattini, Ingrid Pabinger, Jeffrey Weitz

Thromb Haemost· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis